Ankran Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 28-12-2024
- Paid Up Capital ₹ 50.00 K
as on 28-12-2024
- Company Age 8 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.00 M
as on 28-12-2024
- Revenue 262.14%
(FY 2021)
- Profit -83.58%
(FY 2021)
- Ebitda -47.87%
(FY 2021)
- Net Worth 9.96%
(FY 2021)
- Total Assets 173.88%
(FY 2021)
About Ankran Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 50.00 K .
The company currently has active open charges totaling ₹4.00 M.
Parminder Singh and Anjali serve as directors at the Company.
- CIN/LLPIN
U51502PB2016PTC040130
- Company No.
040130
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Mar 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Rupnagar, Punjab, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Ankran Biotech Private Limited offer?
Ankran Biotech Private Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Diclofenac, Anti Infective Drugs & Medicines, Antibacterial Drugs, Nutraceuticals & Dietary Supplements, Mineral Supplement, Respiratory System Drugs, Anti Asthma Drug, Industrial Chemicals & Supplies, Biocides.
Who are the key members and board of directors at Ankran Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Parminder Singh  | Director | 01-Mar-2016 | Current |
| Anjali | Director | 02-Aug-2018 | Current |
Financial Performance of Ankran Biotech.
Ankran Biotech Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 262.14% increase. The company also saw a substantial fall in profitability, with a 83.58% decrease in profit. The company's net worth moved up by a moderate rise of 9.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ankran Biotech?
In 2021, Ankran Biotech had a promoter holding of 50.00% and a public holding of 50.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Amkon Pharmaceuticals Private LimitedActive 3 years 8 months
Parminder Singh and Anjali are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
City Union Bank Limited Creation Date: 02 Jan 2018 | ₹4.00 M | Open |
How Many Employees Work at Ankran Biotech?
Unlock and access historical data on people associated with Ankran Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ankran Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ankran Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
